Anti-cytokine auto-vaccinations as tools for the analysis of cytokine function in vivo

Cytokine and Growth Factor Reviews

Volumn 23, Issue 1-2, 2012, Pages 1-6

  Uyttenhove, Catherine ^a,b   Van Snick, Jacques ^a,b  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^b DE DUVE INSTITUTE   (Belgium)

Author keywords

Chemokine; Cytokine; Tolerance; Vaccine

Indexed keywords

AUTOVACCINE; CYTOKINE; CYTOKINE ANTIBODY; DNA VACCINE; GELATINASE B; GRANULOCYTE CHEMOTACTIC PROTEIN 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 23; INTERLEUKIN 25; INTERLEUKIN 27; INTERLEUKIN 6; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AB4; MONOCLONAL ANTIBODY MM17F3; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR 1; UBIQUITIN; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANTIBODY PRODUCTION; ARTHRITIS; ATHEROSCLEROSIS; B LYMPHOCYTE; CACHEXIA; CYTOKINE PRODUCTION; DRUG HALF LIFE; IMMUNOLOGICAL TOLERANCE; IN VIVO STUDY; INFECTION RESISTANCE; LEISHMANIASIS; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN FUNCTION; SHORT SURVEY; TRICHURIASIS; TUBERCULOSIS; VACCINATION;

ANIMALS; ANTIBODIES; AUTOANTIGENS; AUTOIMMUNITY; CYTOKINES; HUMANS; MICE; MODELS, BIOLOGICAL; RESEARCH DESIGN; VACCINATION;

MUS;

EID: 84858335860     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2011.12.001     Document Type: Short Survey

References (44)

1. Dalum I., Jensen M.R., Hindersson P., Elsner H.I., Mouritsen S. Breaking of B cell tolerance toward a highly conserved self protein. J Immunol 1996, 157:4796-4804.
2. Dalum I., Butler D.M., Jensen M.R., Hindersson P., Steinaa L., Waterston A.M., et al. Therapeutic antibodies elicited by immunization against TNF-alpha. Nat Biotechnol 1999, 17:666-669.
3. Richard M., Louahed J., Demoulin J.-B., Renauld J.-C. Interleukin-9 regulates NF-κB activity through BCL3 gene induction. Blood 1999, 93:4318-4327.
4. Arendse B., Van Snick J., Brombacher F. IL-9 is a susceptibility factor in Leishmania major infection by promoting detrimental Th2/type 2 responses. J Immunol 2005, 174:2205-2211.
5. Veldhoen M., Uyttenhove C., van Snick J., Helmby H., Westendorf A., Buer J., et al. Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol 2008, 9:1341-1346.
6. Wilhelm C., Hirota K., Stieglitz B., Van Snick J., Tolaini M., Lahl K., et al. An IL-9 fate reporter demonstrates the induction of an innate IL-9 response in lung inflammation. Nat Immunol 2011, 12:1071-1077.
7. Dodd J.S., Lum E., Goulding J., Muir R., Van Snick J., Openshaw P.J. IL-9 regulates pathology during primary and memory responses to respiratory syncytial virus infection. J Immunol 2009, 183:7006-7013.
8. Alexander J., Sidney J., Southwood S., Ruppert J., Oseroff C., Maewal A., et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994, 1:751-761.
9. Uyttenhove C., Arendse B., Stroobant V., Brombacher F., Van Snick J. Development of an anti-IL-12 p40 auto-vaccine: protection in experimental autoimmune encephalomyelitis at the expense of increased sensitivity to infection. Eur J Immunol 2004, 34:3572-3581.
10. Hauer A.D., Uyttenhove C., de Vos P., Stroobant V., Renauld J.C., van Berkel T.J., et al. Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation 2005, 112:1054-1062.
11. Freches D., Romano M., Korf H., Renauld J.C., Van Snick J., Uyttenhove C., et al. Increased pulmonary tumor necrosis factor alpha, interleukin-6 (IL-6), and IL-17A responses compensate for decreased gamma interferon production in anti-IL-12 autovaccine-treated, Mycobacterium bovis BCG-vaccinated mice. Clin Vaccine Immunol 2011, 18:95-104.
12. Uyttenhove C., Van Snick J. Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis. Eur J Immunol 2006, 36:2868-2874.
13. Galicia G., Kasran A., Uyttenhove C., De Swert K., Van Snick J., Ceuppens J.L. ICOS deficiency results in exacerbated IL-17 mediated experimental autoimmune encephalomyelitis. J Clin Immunol 2009, 29:426-433.
14. Kelchtermans H., Schurgers E., Geboes L., Mitera T., Van Damme J., Van Snick J., et al. Effector mechanisms of interleukin-17 in collagen-induced arthritis in the absence of interferon-gamma and counteraction by interferon-gamma. Arthritis Res Ther 2009, 11:R122.
15. Lo Re S., Dumoutier L., Couillin I., Van Vyve C., Yakoub Y., Uwambayinema F., et al. IL-17A-producing gammadelta T and Th17 lymphocytes mediate lung inflammation but not fibrosis in experimental silicosis. J Immunol 2011, 184:6367-6377.
16. Taleb S., Romain M., Ramkhelawon B., Uyttenhove C., Pasterkamp G., Herbin O., et al. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med 2009, 206:2067-2077.
17. Ait-Oufella H., Herbin O., Bouaziz J.D., Binder C.J., Uyttenhove C., Laurans L., et al. B cell depletion reduces the development of atherosclerosis in mice. J Exp Med 2010, 207:1579-1587.
18. Uyttenhove C., Marillier R.G., Tacchini-Cottier F., Charmoy M., Caspi R.R., Damsker J.M., et al. Amine-reactive OVA multimers for auto-vaccination against cytokines and other mediators: perspectives illustrated for GCP-2 in L. major infection. J Leukoc Biol 2011, 89:1001-1007.
19. Gijsbers K., Gouwy M., Struyf S., Wuyts A., Proost P., Opdenakker G., et al. GCP-2/CXCL6 synergizes with other endothelial cell-derived chemokines in neutrophil mobilization and is associated with angiogenesis in gastrointestinal tumors. Exp Cell Res 2005, 303:331-342.
20. Verbeke H., Struyf S., Berghmans N., Van Coillie E., Opdenakker G., Uyttenhove C., et al. Isotypic neutralizing antibodies against mouse GCP-2/CXCL6 inhibit melanoma growth and metastasis. Cancer Lett 2011, 302:54-62.
21. Le Buanec H., Paturance S., Couillin I., Schnyder-Candrian S., Larcier P., Ryffel B., et al. Control of allergic reactions in mice by an active anti-murine IL-4 immunization. Vaccine 2007, 25:7206-7216.
22. Le Buanec H., Delavallee L., Bessis N., Paturance S., Bizzini B., Gallo R., et al. TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation. Proc Natl Acad Sci U S A 2006, 103:19442-19447.
23. Rad F.H., Le Buanec H., Paturance S., Larcier P., Genne P., Ryffel B., et al. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci U S A 2007, 104:2837-2842.
24. Zagury D., Le Buanec H., Mathian A., Larcier P., Burnett R., Amoura Z., et al. IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc Natl Acad Sci U S A 2009, 106:5294-5299.
25. Ratsimandresy R.A., Duvallet E., Assier E., Semerano L., Delavallee L., Bessis N., et al. Active immunization against IL-23p19 improves experimental arthritis. Vaccine 2011, 29:9329-9336.
26. Bertin-Maghit S.M., Capini C.J., Bessis N., Chomilier J., Muller S., Abbas A., et al. Improvement of collagen-induced arthritis by active immunization against murine IL-1beta peptides designed by molecular modelling. Vaccine 2005, 23:4228-4235.
27. Bachmann M., Hoffmann Rorher U., Kündig T.M., Bürki K., Hengartner H., Zinkernagel R.M. The influence of antigen organization on B cell responsiveness. Science 1993, 262:1448-1451.
28. Kirnbauer R., Chandrachud L.M., O'Neil B.W., Wagner E.R., Grindlay G.J., Armstrong A., et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 1996, 219:37-44.
29. Sonderegger I., Rohn T.A., Kurrer M.O., Iezzi G., Zou Y., Kastelein R.A., et al. Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J Immunol 2006, 36:2849-2856.
30. Rohn T.A., Jennings G.T., Hernandez M., Grest P., Beck M., Zou Y., et al. Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol 2006, 36:2857-2867.
31. Ma Y., HayGlass K.T., Becker A.B., Fan Y., Yang X., Basu S., et al. Novel recombinant interleukin-13 peptide-based vaccine reduces airway allergic inflammatory responses in mice. Am J Respir Crit Care Med 2007, 176:439-445.
32. Ma Y., Hayglass K.T., Becker A.B., Halayko A.J., Basu S., Simons F.E., et al. Novel cytokine peptide-based vaccines: an interleukin-4 vaccine suppresses airway allergic responses in mice. Allergy 2007, 62:675-682.
33. Hertz M., Mahalingam S., Dalum I., Klysner S., Mattes J., Neisig A., et al. Active vaccination against IL-5 bypasses immunological tolerance and ameliorates experimental asthma. J Immunol 2001, 167:3792-3799.
34. Morimoto S., Kanno Y., Tanaka Y., Tokano Y., Hashimoto H., Jacquot S., et al. CD134L engagement enhances human B cell Ig production: CD154/CD40, CD70/CD27, and CD134/CD134L interactions coordinately regulate T cell-dependent B cell responses. J Immunol 2000, 164:4097-4104.
35. Lemaire M.M., Vanhaudenarde A., Nizet Y., Dumoutier L., Renauld J.C. Induction of autoantibodies against mouse soluble proteins after immunization with living cells presenting the autoantigen at the cell surface in fusion with a human type 2 transmembrane protein. J Immunol Methods 2011, 367:56-62.
36. Van Pel A., De Plaen E., Boon T. Selection of a highly transfectable variant from mouse mastocytoma P815. Som Cell Genet 1985, 11:467-475.
37. Gillet L., Schroeder H., Mast J., Thirion M., Renauld J.C., Dewals B., et al. Anchoring tick salivary anti-complement proteins IRAC I and IRAC II to membrane increases their immunogenicity. Vet Res 2009, 40:51.
38. Kim J.J., Ayyavoo V., Bagarazzi M.L., Chattergoon M.A., Dang K., Wang B., et al. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol 1997, 158:816-826.
39. Waisman A., Ruiz P.J., Hirschberg D.L., Gelman A., Oksenberg J.R., Brocke S., et al. Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity. Nat Med 1996, 2:899-905.
40. Youssef S., Wildbaum G., Maor G., Lanir N., Gour-Lavie A., Grabie N., et al. Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding CC chemokines. J Immunol 1998, 161:3870-3879.
41. Shen Y., Chen J., Zhang X., Wu X., Xu Q. Human TNF-alpha gene vaccination prevents collagen-induced arthritis in mice. Int Immunopharmacol 2007, 7:1140-1149.
42. Johnson H.E., DeAvila D.M., Chang C.F., Reeves J.J. Active immunization of heifers against luteinizing hormone-releasing hormone, human chorionic gonadotropin and bovine luteinizing hormone. J. Anim. Sci. 1988, 66:719-726.
43. Talwar G.P., Singh O., Pal R., Chatterjee N., Sahai P., Dhall K., et al. A vaccine that prevents pregnancy in women. Proc Natl Acad Sci USA 1994, 91:8532-8536.
44. Ratsimandresy R.A., Rappaport J., Zagury J.F. Anti-cytokine therapeutics: history and update. Curr Pharm Des 2009, 15:1998-2025.